Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Coagulation Factor VIII for Injection in Severe Hemophilia A (On-demand and Prophylaxis)
CTR20231408Phase 3Completed
- Sponsor
- Zhuangya Biotech
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Zhuangya Biotech. Started May 2023; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20231408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231408.